Kidney Neoplasms
Conditions
Brief summary
Patients with renal masses eligible to partial nephrectomy often require arterial ischemia to control or prevent blood loss during this surgical procedure. This study aims to determine the safety and efficacy of renal cryoablation at the tumor bed, as a substitute measure or technique vs total or selective arterial renal ischemia.
Detailed description
Nephron sparring surgery has emerged as the procedure of choice for most patients with renal tumors that are \>2 cm and harbor a greater than 50% exophitic component. In order to decrease blood loss surgeons may: 1- interrupt blood flow to the kidney, completely or selectively; 2-Use diuretics such as mannitol to dehydrate the kidney; 3-Ice externally the kidney - in open procedures - to decrease metabolism during ischemia. The emergence of robotic surgery triggered a shift in the the surgical approach to partial nephrectomy and is commonly employed. A fundamental drawback of this technique is represented on the lack of cold ischemia. However, warm ischemia is commonly employed and requires dissection of the renal pedicle, which by itself puts the kidney at risk of loss.
Interventions
DEVICECryoablation Assisted Partial Nephrectomy
Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
Sponsors
Urological Research Network, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients are scheduled for a surgical procedure: robotic partial nephrectomy, and the investigators will use a cryoablation probe(s) for selective ischemia rather than full blood flow interruption with a vascular clamp
Eligibility
Sex/Gender
ALL
Age
55 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with ages between 45-90-year-old. * Renal tumor ≤ 7 cm in the greatest extension, \>50% exophitic.
Exclusion criteria
* Prior renal surgery * M1 Disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence - Oncological Control | 10 Years | Recurrence at Site of Excision or within 1 cm of margin or Development of Metastasis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local Re-Intervention | 10 Years | Either subsequent ablation or surgical exploration or surgical kidney removal |
| Development or Progression of Chronic Kidney Disease (CKD) | 10 Years | De-Novo emergence of CDK or changes in CKD overtime based on variation from baseline. The international classification for CKD defined by serum estimated Glomerular Filtration Rates (GFR) will be used as measurement instrument using the following definitions: GFR categories in CKD G1 ≥90 Normal or high G2 60-89 Mildly decreased\* G3a 45-59 Mildly to moderately decreased G3b 30-44 Moderately to severely decreased |
| Incidence of Metastatic disease | 10 Years | patients will be evaluated using imaging studies at fixed intervals as follows: at 6 months Renal Ultrasound at 1 year CT Urogram at 18 Months, 24 months and yearly thereafter with Renal Ultrasound CT Urograms will be performed as needed for cause |
| Survival | 10 years | If a patient expiries during the study interval we would procure the death certificate and do our best to determine cause of death |
Countries
United States
Contacts
Primary ContactEusebio J Luna, MD
Backup ContactCielo Guerra
Outcome results
None listed